...
首页> 外文期刊>Arthritis care & research >Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: bone mineral density measurements in a multicenter randomized clinical trial.
【24h】

Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: bone mineral density measurements in a multicenter randomized clinical trial.

机译:类风湿关节炎患者手骨矿物质密度的变化及其与疾病活动水平的关系:多中心随机临床试验中骨矿物质密度的测量。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To determine if metacarpal bone mineral density (mBMD) gain occurs in patients with rheumatoid arthritis (RA). If mBMD loss is driven by inflammation, we expect to find mBMD gain in patients who are in remission. METHODS: mBMD was measured by digital x-ray radiogrammetry in consecutive radiographs of 145 patients with RA with either continuous high disease activity (HDA; Disease Activity Score [DAS] >2.4), low disease activity (LDA; 1.6 >/= DAS /=4.6 mg/cm2/year), compared to 2% of the patients with HDA and 5% of the patients with LDA. Patients in CR had a higher chance of having mBMD gain, compared with LDA and HDA (relative risk [RR] 14.9, 95% confidence interval [95% CI] 3.0-18.7 and RR 4.7, 95% CI 1.2-6.3, respectively). CR, hormone replacement therapy, and lower age were significant independent predictors of mBMD gain. CONCLUSION: In RA, mBMD gain occurs primarily in patients in continuous (>/=1 year) CR and rarely in patients with continuous HDA or LDA. This suggests that mBMD loss is driven by inflammation.
机译:目的:确定类风湿关节炎(RA)患者是否发生掌骨密度(mBMD)的增加。如果mBMD的丧失是由炎症驱动的,那么我们希望在缓解的患者中发现mBMD的获得。方法:通过数字X射线照相术对145例患有持续高疾病活动(HDA;疾病活动评分[DAS]> 2.4),低疾病活动(LDA; 1.6> / = DAS < / = 2.4),或在1年观察期内连续临床缓解(CR; DAS <1.6)。用多项式回归分析研究了mBMD变化与疾病活动的关系。接下来,确定与mBMD增益相关的临床变量。结果:CR患者的mBMD平均变化为-0.03%,而HDA和LDA患者分别为-3.13%和-2.03%(总体,P <0.001)。在CR的患者中,有32%的患者发生mBMD丢失(小于或等于-4.6 mg / cm2 /年),而HDA或LDA患者分别为62%和66%,而在HDA或LDA患者中为26% CR的mBMD增高(> / = 4.6 mg / cm2 /年),相比之下,HDA患者为2%,LDA患者为5%。与LDA和HDA相比,CR患者的mBMD增高机会更高(相对风险[RR] 14.9,95%置信区间[95%CI] 3.0-18.7和RR 4.7,95%CI 1.2-6.3) 。 CR,激素替代疗法和较低年龄是mBMD增高的重要独立预测因子。结论:在RA中,mBMD增加主要发生在连续(> / = 1年)CR患者中,很少发生在连续HDA或LDA患者中。这表明mBMD的丧失是由炎症驱动的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号